HE Bays, PB Moore, MA Drehobl, S Rosenblatt, PD … - Clinical therapeutics, 2001 - Elsevier Methods: After dietary stabilization (National Cholesterol Education Program Step I diet or a stricter
diet), washout of lipid-altering drugs, and a 6-week placebo lead-in period, patients with baseline
plasma low-density lipoprotein cholesterol (LDL-C) levels ≥130 and ≤250 mg/dL and ... Cited by 182 - Related articles - BL Direct - All 8 versions
- ►ahajournals.org HR Davis Jr, DS Compton, L Hoos, G … - … , thrombosis, and vascular …, 2001 - Am Heart Assoc Ezetimibe (SCH58235) is a potent, selective, cholesterol absorption inhibitor. The objective of
this study was to determine whether ezetimibe reduces plasma cholesterol and inhibits atherogenesis
in apolipoprotein E knockout (apoE-/-) mice. Cholesterol absorption was inhibited by ... Cited by 140 - Related articles - BL Direct - All 9 versions
M Van Heek, C Farley, DS Compton, L … - British journal of …, 2001 - pubmedcentral.nih.gov Ezetimibe reduced plasma cholesterol and hepatic cholesterol accumulation in cholesterol-fed
hamsters with an ED 50 of 0.04 mg kg −1 . Utilizing cholesteryl esters labelled on either the cholesterol
or the fatty acid moiety, we demonstrated that ezetimibe did not affect cholesteryl ester ... Cited by 132 - Related articles - BL Direct - All 4 versions
- ►jlr.org JJ Repa, JM Dietschy, SD Turley - The Journal of Lipid Research, 2002 - ASBMB Intestinal cholesterol absorption is a major determinant of plasma low density lipoprotein-cholesterol
(LDL-C) concentrations. Ezetimibe (SCH 58235) and its analogs SCH 48461 and SCH 58053
are novel potent inhibitors of cholesterol absorption whose mechanism of action is ... Cited by 68 - Related articles - BL Direct - All 4 versions
- ►adisonline.com [PDF] T Sudhop, K Von Bergmann - Drugs, 2002 - ingentaconnect.com Abstract The benefits of lipid lowering therapy on coronary heart disease have been clearly established
in many clinical trials on primary and secondary prevention. Despite the availability of potent
lipid lowering drugs, many patients do not reach the current treatment goals. This paper ... Cited by 67 - Related articles - BL Direct - All 8 versions
LA Jeu, JWM Cheng - Clinical therapeutics, 2003 - Elsevier Results: In adults, ezetimibe 10 mg PO given once daily has been reported to reduce intestinal
cholesterol absorption by 54% from baseline in association with a compensatory increase in
endogenous cholesterol synthesis. Within 2 weeks of its initiation, ezetimibe monotherapy ... Cited by 52 - Related articles - All 5 versions
- ►jlr.org JJ Repa, SD Turley, G Quan, JM Dietschy - The Journal of Lipid Research, 2005 - ASBMB The absorption of cholesterol by the small intestine is a major route for the net entry of cholesterol
into the body and can therefore affect the plasma low density lipoprotein-cholesterol (LDL-C)
concentration. These studies used ezetimibe, a potent inhibitor of cholesterol absorption, ... Cited by 31 - Related articles - All 6 versions
M van Heek, C Farley, DS Compton, LM … - British journal of …, 2003 - pubmedcentral.nih.gov After a dose response for ezetimibe in rats was established, experiments were conducted to
determine whether acute administration could alter hepatic or intestinal cholesterol
synthesis. To determine whether this class of intestinal cholesterol absorption inhibitors ... Cited by 29 - Related articles - BL Direct - All 5 versions
DA Burnett - Current medicinal chemistry, 2004 - ingentaconnect.com Abstract: β-Lactams have recently been identified as potent, highly efficacious cholesterol absorption
inhibitors (CAIs). The discovery, SAR, and asymmetric synthesis of this class of hypolipidemic
agents are described. Metabolism studies of the first clinical candidate, Sch 48461, led to ... Cited by 26 - Related articles - BL Direct - All 5 versions
